Top

A -- Preclinical Toxicology and Pharmacology of Drugs Developed for Cancer, AIDS, and AID-related Illnesses

Active

N01-CM-87028Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

The National Cancer Institute's Development Therapeutics Program plans to extend existing contracts by seven months with Battelle Memorial Institute, Southern Research Institute, SRI International, and the University of Illinois at Chicago. This extension will ensure uninterrupted support for the Preclinical Toxicology and Pharmacology of Drugs program focused on treatments for cancer, AIDS, and related illnesses. The original contracts were set to expire on July 14, 2003, but delays in issuing a new Request for Proposals have pushed back the timeline for award decisions until February 2004. This non-competitive extension allows ongoing research critical to clinical trials to continue without disruption. During this extension period, the NCI intends to announce a full and open competition for future contract awards, structured as a Cost-Plus Fixed Fee, Completion contract. Although the re-competition will be publicized on the Research Contracts Branch website, proposals are not currently being solicited. This measure is a stopgap to maintain momentum in essential research while preparing for a competitive procurement process moving forward. The contract relates specifically to the continuation of important preclinical testing activities for drugs aimed at treating cancer and AIDS-related conditions.

General Info

NCI extends contracts seven months with four institutes for uninterrupted preclinical drug research.

Agency

N/A

NAICS

541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Place of Performance

Not specified

Set-Aside

NONE

Documents

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PostedJun 25

special-notice

Ready to pursue this opportunity?

Get full access to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

AgencyN/A

ContactsNo contacts available

OfficeN/A

Organization / Agency

N/A

Office AddressN/A

ContactsNo contact information available

Full Description

The National Cancer Institute (NCI), Development Therapeutics Program, Division of Cancer Treatment and Diagnosis, intends to enter into a (7) seven-month contract extension with Battelle Memorial Institute, Southern Research Institute, SRI International and University of Illinois at Chicago, to provide uninterrupted continuation support to the Preclinical Toxicology and Pharmacology of Drugs Developed for Cancer, AIDS, and AIDS-related Illnesses program. The period of performance and dollar values negotiated in the original contracts were supposed to last until July 14, 2003; however the follow-on Request for proposals (RFP) has been delayed and the new awards are not anticipated be made until February 2004. To ensure uninterrupted continuation of essential research in support of clinical trials, this non-competitive acquisition is proposed for a period of seven months. During this seven-month period the NCI intends to announce a full and open competition for its future requirements in this area, as a Cost-Plus Fixed Fee, Completion contract. During this time frame, the re-competition will be announced, and the RFP will be found on the Research Contracts Branch home page (http://rcb.cancer.gov/rcb-internet/appl/rfp/published_rfps.jsp). Proposals are not being requested at this time. No collect calls will be accepted. Numbered Note 22 is referenced.

Similar Contracts

Same NAICS industry code